ESR2 and breast carcinoma: The discovery of ERβ in 1996 as the second nuclear receptor for steroid/thyroid hormones (i.e., 17β-estradiol, E2), after ERα, reserved a new era in the diagnosis, survival estimation and therapeutic targeting of breast cancer (12).